Outlook Therapeutics is a late clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a complex, technically challenging and commercially attractive monoclonal antibody, or mAb, for various ophthalmic indications.
Would you like to join our team?
© 2018-2025 Outlook Therapeutics, Inc.
This site is intended for a US audience only.
Privacy Policy | Disclaimer | Terms of use
This website contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations, estimates, and projections, and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements. We undertake no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Readers are cautioned not to place undue reliance on these forward-looking statements.
